Saad Z. Usmani, MD, discusses the combination of carfilzomib and filanesib as a treatment for multiple myeloma.
Saad Z. Usmani, MD, director, Plasma Cells Disorder Program, Levine Cancer Institute/Carolinas Healthcare System, discusses the combination of carfilzomib and filanesib as a treatment for multiple myeloma. Usmani said a recent phase II study showcased a response rate of 14% in the carfilzomib-only arm, while a response rate of 35% was seen in the arm with patients receiving a combination of carfilzomib and filanesib.
Usmani said the regimen was efficacious, though the main question still persisting post study is how much dosing of carfilzomib should be included in an upcoming phase III study.
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More